about
Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease.Interleukin-6 and asymmetric dimethylarginine are associated with platelet activation after percutaneous angioplasty with stent implantation.Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac CatheterizationNew highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptorsSynergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.Hereditary amyloidosis caused by R554L fibrinogen Aα-chain mutation in a Spanish family and review of the literature.Platelet Physiology.Oral antiplatelet therapy: impact for transfusion medicine.Research update for articles published in EJCI in 2013.Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.The Antiplatelet Effect of Clopidogrel Decreases With Patient Age.In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization.Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy.Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.Response to antiplatelet therapy is independent of endogenous thrombin generation potential.Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors.Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests.Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy.Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy.The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity.Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year.Sublingual functional capillary rarefaction in chronic heart failure.Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease.Circulating microRNAs identify patients at increased risk of in-stent restenosis after peripheral angioplasty with stent implantation.Correction: Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease.Underlying mechanism and specific prevention of hemolysis-induced platelet activation.Plasminogen activator inhibitor-1 4G/5G genotype and residual venous occlusion following acute unprovoked deep vein thrombosis of the lower limb: A prospective cohort study.Impact of diabetes on platelet activation in different manifestations of atherosclerosis.Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.Sex differences of leukocyte-platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis.β-blockers are associated with decreased leucocyte-platelet aggregate formation and lower residual platelet reactivity to adenosine diphosphate after angioplasty and stenting.Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis.
P50
Q31083437-499F988D-57F5-4C5B-8458-435AE442F198Q33399119-F8BC9902-448C-4D3A-8AC3-8F7C3F902171Q33886520-1B9A6D7A-16AA-4535-A5E0-96521DF01AE2Q35216871-7CC600EE-28A3-44F1-837A-08934EC85CCDQ35658513-5A8398E2-19DD-484A-8235-91D2C867D75DQ35735264-A2D3FF7C-23B6-475C-A4E6-18B165A84E8FQ36359617-B97D38C2-9A5F-4342-9BB6-57A17F89DDA4Q36619562-8CB34017-C9B9-4D2F-A54F-8082F0DF134EQ38095581-611BAB55-16BC-47F5-8C1A-D96647585FFFQ38754872-AB66AFEB-4A15-4F51-A790-AD05F92E3853Q38754884-9CBCC588-1813-4CD1-BB05-730B331B98C5Q38852737-017040CC-985E-42A3-A66D-ECB1AA0E1D37Q39281529-D337D09E-650A-4BE8-B76E-FE6FA48E1D36Q39940091-1750B9D9-2FC3-466A-B8DC-1B165C37FAA6Q40009280-8A28A736-021A-4771-9B3F-1FFE7FC3AA6CQ40335176-991BB1E9-9EDF-428C-816C-880F5E57AACDQ41620557-5CD2DE31-005B-4DD3-B99C-6222752213A6Q42972735-CBA0B2E2-77C1-4884-BFFC-F3B16CC28862Q43498064-83E33C6D-7C23-4683-94E7-8C5688E4A1DCQ44011155-F141AF64-6946-4BF1-8624-4C686622C867Q44434674-62A632E1-99C0-4669-964C-9FF89F40DA04Q44970528-B343607A-4703-489B-8FEF-30B4703A4A0AQ45145788-BE643ED3-9531-4149-8ABF-389F3020BDA4Q45344767-40B861AE-A9F3-449C-99F5-69FAC3500992Q45905300-B0045725-3BC0-40A3-914E-ABCAD69FEBFDQ45920395-42B53863-AA1F-4056-B31B-7DE5FBB9500AQ45925768-EFF0C89E-1865-49D0-BBEF-9AC0734D2A07Q46670972-8D54A99C-FE8F-4DB9-9FB6-C6B90F488611Q47227141-5DA13DEE-3893-4459-9B31-24B6EE102F26Q47419470-C9FFBCB9-C5DC-44CB-B826-D8DCC71C4F52Q47666229-13C7D779-89E3-48A6-A0FF-95A0528E485AQ49791606-D0365D7F-C58C-4A3D-B6ED-E72C925BF627Q49791748-D0954C43-1160-479B-B8A0-164D77F0CB9BQ50223961-BEF89F09-DDAE-4087-95CD-BAFDBC6B0A85Q50770027-52000A37-BF71-49A4-A19C-7FE8A99AF746Q50933231-B94A9D82-0141-4FDF-8DBF-32A585E38016Q51049601-437DFFB4-E617-41C8-BD4E-07D5AA089714Q51071891-57354F8A-A331-4283-9BC8-9E6CB3FD6E6EQ51119287-58DDC85F-2D94-4A71-9249-33B2E5FF3D67Q51686114-8D964140-EF5D-44F8-BD42-BD7FC8D67C5F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thomas Gremmel
@ast
Thomas Gremmel
@en
Thomas Gremmel
@es
Thomas Gremmel
@nl
Thomas Gremmel
@sl
type
label
Thomas Gremmel
@ast
Thomas Gremmel
@en
Thomas Gremmel
@es
Thomas Gremmel
@nl
Thomas Gremmel
@sl
prefLabel
Thomas Gremmel
@ast
Thomas Gremmel
@en
Thomas Gremmel
@es
Thomas Gremmel
@nl
Thomas Gremmel
@sl
P106
P21
P31
P496
0000-0001-9554-7292